TransMedics Group, Inc.
TransMedics Group, Inc. (TMDX) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for TransMedics Group, Inc. (TMDX), featuring income statements, balance sheets, and cash flow data.
TransMedics Group, Inc. (TMDX) Income Statement & Financial Overview
View the income breakdown for TransMedics Group, Inc. TMDX across both annual and quarterly reports.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $143.54M | $121.62M | $108.76M | $114.31M |
| Cost of Revenue | $55.31M | $49.61M | $47.92M | $45.14M |
| Gross Profit | $88.23M | $72.01M | $60.84M | $69.16M |
| Gross Profit Ratio | $0.61 | $0.59 | $0.56 | $0.61 |
| R&D Expenses | $17.16M | $16.46M | $14.27M | $13.86M |
| SG&A Expenses | $43.63M | $46.91M | $42.66M | $42.80M |
| Operating Expenses | $60.78M | $63.37M | $56.92M | $56.65M |
| Total Costs & Expenses | $116.09M | $112.98M | $104.84M | $101.80M |
| Interest Income | $0.00 | $2.92M | $3.30M | $3.40M |
| Interest Expense | $3.46M | $3.57M | $3.62M | $3.62M |
| Depreciation & Amortization | $6.14M | $5.68M | $9.12M | $4.60M |
| EBITDA | $36.27M | $16.24M | $13.04M | $17.11M |
| EBITDA Ratio | $0.25 | $0.13 | $0.12 | $0.15 |
| Operating Income | $27.44M | $8.64M | $3.92M | $12.51M |
| Operating Income Ratio | $0.19 | $0.07 | $0.04 | $0.11 |
| Other Income/Expenses (Net) | -$767000.00 | -$1.66M | $322000.00 | -$355000.00 |
| Income Before Tax | $26.68M | $6.99M | $4.25M | $12.15M |
| Income Before Tax Ratio | $0.19 | $0.06 | $0.04 | $0.11 |
| Income Tax Expense | $994000.00 | $132000.00 | $29000.00 | -$41000.00 |
| Net Income | $25.68M | $6.86M | $4.22M | $12.19M |
| Net Income Ratio | $0.18 | $0.06 | $0.04 | $0.11 |
| EPS | $0.76 | $0.20 | $0.13 | $0.37 |
| Diluted EPS | $0.70 | $0.19 | $0.12 | $0.35 |
| Weighted Avg Shares Outstanding | $33.72M | $33.59M | $33.44M | $33.12M |
| Weighted Avg Shares Outstanding (Diluted) | $39.91M | $35.21M | $35.68M | $35.29M |
Financial performance has remained strong, with revenue growing from $114.31M in Q2 2024 to $143.54M in Q1 2025. Gross profit continued to perform well, with margins at 61% in the latest quarter. Operating income reached $27.44M in Q1 2025, holding a steady 19% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $36.27M. Net income rose to $25.68M, keeping EPS at $0.76. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan